There is a lot of technical language around IgAN and it can seem confusing and overwhelming when receiving a diagnosis for yourself or a loved one. You may have many questions regarding what it is, how it effects your body, how you got it, and the treatment course that may be available to you. The […]
Read MoreThe NKF and IGANF conducted an EL-PFDD meeting on IgAN to inform the FDA on the patient perspective on living with this disease. Understanding the patient perspective will help the FDA when it decides whether to approve potential medicines for IgAN. On August 19, 2019, the National Kidney Foundation and the IGA Nephropathy Foundation of […]
Read MoreSupport Continued Coverage for ESRD One of the most common organs to fail, get cancer or need support is the kidneys. Most of us know someone or many people who have to receive dialysis and are on the waiting list of a new kidney. Did you know the care and coverage of the services needed […]
Read MoreAbstract The randomized, controlled STOP-IgAN trial in patients with IgA nephropathy (IgAN) and substantial proteinuria showed no benefit of immunosuppression added on top of supportive care on renal function over three years. As a follow-up we evaluated renal outcomes in patients over a follow-up of up to ten years in terms of serum creatinine, proteinuria, […]
Read MoreAbstract IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative projectwas toidentify surrogate end points that could serve as reliable predictors of a treatment’s […]
Read MoreBrussels, Belgium Recognizing the need for more precise, consistent, and patient-centered nomenclature describing kidney function and disease, Kidney Disease: Improving Global Outcomes (KDIGO) organized a consensus conference in June 2019. The meeting was attended by diverse stakeholders, including clinicians caring for persons with kidney disease, patients, researchers, and editors of all major kidney journals as […]
Read MoreThe Honorable Richard Shelby Chair, Senate Committee on Appropriations 304 Russell Senate Office Building Washington, DC 20510 The Honorable Roy Blunt Chair, Subcommittee on Labor, Health and Human Services, Education and Related Agencies 347 Russell Senate Office Building Washington, DC 20510 The Honorable Patrick Leahy Ranking Member, Senate Committee on Appropriations 437 Russell Senate Office […]
Read MoreThe Honorable Nita Lowey Chair, House Committee on Appropriations 2365 Rayburn House Office Building Washington, DC 20515-3217 The Honorable Rosa DeLauro Chair, Subcommittee on Labor, Health and Human Services, Education and Related Agencies 2413 Rayburn House Office Building Washington, DC 20515-0703 The Honorable Kay Granger Ranking Member, House Committee on Appropriations 1026 Longworth House Office […]
Read MoreDiagnosis of IgA nephropathy The diagnostic feature of immunoglobulin A (IgA) nephropathy (IgAN) is the substantial accumulation of IgA in the filtering structures (glomeruli) of the kidneys. When IgAN was first described in 1968, most patients also had another antibody, IgG, in the glomeruli. The diagnosis of IgAN does not however require IgG to be […]
Read MoreVolume 04| April 3, 2020 IgA Nephropathy Foundation News New Members We would like to start off by welcoming our new patients to our IGAN family. Welcome!!! If you need anything at all, please contact carrie@igan.org or bonnie@igan.org. We are always here for you! COVID-19 Update This is a very uncertain time for all of […]
Read More